MEDLIB-L Archives

November 2019, Week 5

MEDLIB-L@LIST.UVM.EDU
Options: Use Monospaced Font
Show Text Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Subject:
ILL: J Investig Allergol Clin Immunol , 7 (3), 151-4 May-Jun 1997
From:
Gerardo Gutierrez <[log in to unmask]>
Reply To:
Gerardo Gutierrez <[log in to unmask]>
Date:
Fri, 29 Nov 2019 08:13:42 -0600
Content-Type:
text/plain
Parts/Attachments:
text/plain (53 lines) 
Dear group

Good morning, please your help with this article

J Investig Allergol Clin Immunol

   -
   <https://pubmed.ncbi.nlm.nih.gov/?term=%22J+Investig+Allergol+Clin+Immunol%22%5Bjour%5D>
   -
   <https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J+Investig+Allergol+Clin+Immunol%22[Title+Abbreviation]>
   -
   <https://pubmed.ncbi.nlm.nih.gov/9252872-nonfatal-systemic-reactions-to-subcutaneous-immunotherapy-a-10-year-experience/#>

, 7 (3), 151-4
 May-Jun 1997Nonfatal Systemic Reactions to Subcutaneous Immunotherapy: A
10-year Experience
F V Ragusa
<https://pubmed.ncbi.nlm.nih.gov/?term=Ragusa+FV&cauthor_id=9252872>, G
Passalacqua
<https://pubmed.ncbi.nlm.nih.gov/?term=Passalacqua+G&cauthor_id=9252872>
 ... G W Canonica
<https://pubmed.ncbi.nlm.nih.gov/?term=Canonica+GW&cauthor_id=9252872>expand

   - PMID: 9252872

Abstract

The present retrospective study reviews our clinical experience with
Subcutaneous immunotherapy (SIT) over a 10 year period (1981-1991), in
order to assess both incidence and clinical features of nonfatal systemic
reactions due to this treatment. 192,505 injections were globally
administered to 2,206 outpatients, following the suggested precautionary
guidelines. We observed 115 systemic reactions (5.2% of patients and 0.06%
of injections) and no fatalities. The association asthma + urticaria was
the most frequent reaction (67%), followed by asthma alone (22%). No risk
factor related to age, gender, pollen season or manufacturer was observed.
The occurrence of systemic reactions was highly frequent in asthmatic
patients, but approximately 1/3 of the patients who presented reactions had
never previously suffered from asthma. The largest part of the observed
reactions occurred during the maintenance phase of treatment. Almost all
adverse events occurred within 30 minutes after the injection and they were
promptly controlled by routine therapy. We conclude that subcutaneous
immunotherapy, if performed with careful compliance to good clinical
practice rules, is a safe treatment for respiratory allergy.



Gerardo Gutierrez

Medical Librarian

Edufarm

ATOM RSS1 RSS2